Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dextroamphetamine Clear all
Completed Phase 4 Interventional Results available

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

NCT03446885
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Lisdexamfetamine Dimesylate 40 MG, Placebo
Drug
Lead sponsor
Gregory Fabiano
Other
Eligibility
16 Years to 25 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Amphetamine-Enhanced Stroke Recovery

NCT01905371
View directory record Official record
Conditions
Stroke
Interventions
Dextroamphetamine, Physical Therapy, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

NCT01291173
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
lisdexamfetamine dimesylate (SPD489), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Matching placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00807222
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Sleep
Interventions
lisdexamfetamine dimesylate
Drug
Lead sponsor
Clinical Study Centers, LLC
Other
Eligibility
6 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2008 · Synced Sep 2, 2026, 5:35 AM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of D-amphetamine on Reward Functioning

NCT03369015
View directory record Official record
Conditions
Anhedonia
Interventions
10 mg d-amphetamine, 20mg d-amphetamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 35 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence

NCT00630682
View directory record Official record
Conditions
Methamphetamine Addiction
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IMProving Executive Function Study

NCT03187353
View directory record Official record
Conditions
Cognitive Impairment, RRSO
Interventions
Lisdexamfetamine, Placebo oral capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 58 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Results available

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

NCT01457339
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Monoamine Contributions to Neurocircuitry in Eating Disorders

NCT02020408
View directory record Official record
Conditions
Eating Disorder
Interventions
[11C]raclopride, [11C]DASB, amphetamine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

NCT01486810
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Lisdexamfetamine, medication management
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Stimulant Effects on Disruptive Behavior

NCT03420339
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions
Stimulant
Drug
Lead sponsor
Matthew J O'Brien, PhD, BCBA-D
Other
Eligibility
48 Months to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading

NCT00733356
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Vyvanse
Drug
Lead sponsor
Kimberley Lakes
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 2, 2026, 5:35 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

NCT03999190
View directory record Official record
Conditions
Schizophrenia
Interventions
NPA radiotracer, Raclopride radiotracer, Dextroamphetamine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 2, 2026, 5:35 AM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04414930
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-amphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Dextroamphetamine and tDCS to Improve the Fluency

NCT02514044
View directory record Official record
Conditions
Stroke
Interventions
Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS
Drug · Device · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

NCT00764868
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine Dimesylate (LDX)
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 5:35 AM EDT